417 related articles for article (PubMed ID: 31118200)
21. MiR-873/PD-L1 axis regulates the stemness of breast cancer cells.
Gao L; Guo Q; Li X; Yang X; Ni H; Wang T; Zhao Q; Liu H; Xing Y; Xi T; Zheng L
EBioMedicine; 2019 Mar; 41():395-407. PubMed ID: 30803931
[TBL] [Abstract][Full Text] [Related]
22. Employing mesenchymal stem cells to support tumor-targeted delivery of extracellular vesicle (EV)-encapsulated microRNA-379.
O'Brien KP; Khan S; Gilligan KE; Zafar H; Lalor P; Glynn C; O'Flatharta C; Ingoldsby H; Dockery P; De Bhulbh A; Schweber JR; St John K; Leahy M; Murphy JM; Gallagher WM; O'Brien T; Kerin MJ; Dwyer RM
Oncogene; 2018 Apr; 37(16):2137-2149. PubMed ID: 29367765
[TBL] [Abstract][Full Text] [Related]
23. CCL16 maintains stem cell-like properties in breast cancer by activating CCR2/GSK3β/β-catenin/OCT4 axis.
Shen W; Zhang X; Tang J; Zhang Z; Du R; Luo D; Liu X; Xia Y; Li Y; Wang S; Yan S; Yang W; Xiang R; Luo N; Luo Y; Li J
Theranostics; 2021; 11(5):2297-2317. PubMed ID: 33500726
[No Abstract] [Full Text] [Related]
24. Transcriptional factor six2 promotes the competitive endogenous RNA network between CYP4Z1 and pseudogene CYP4Z2P responsible for maintaining the stemness of breast cancer cells.
Zheng L; Guo Q; Xiang C; Liu S; Jiang Y; Gao L; Ni H; Wang T; Zhao Q; Liu H; Xing Y; Wang Y; Li X; Xi T
J Hematol Oncol; 2019 Mar; 12(1):23. PubMed ID: 30832689
[TBL] [Abstract][Full Text] [Related]
25. A Sox2:miR-486-5p Axis Regulates Survival of GBM Cells by Inhibiting Tumor Suppressor Networks.
Lopez-Bertoni H; Kotchetkov IS; Mihelson N; Lal B; Rui Y; Ames H; Lugo-Fagundo M; Guerrero-Cazares H; Quiñones-Hinojosa A; Green JJ; Laterra J
Cancer Res; 2020 Apr; 80(8):1644-1655. PubMed ID: 32094299
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-205 signaling regulates mammary stem cell fate and tumorigenesis.
Chao CH; Chang CC; Wu MJ; Ko HW; Wang D; Hung MC; Yang JY; Chang CJ
J Clin Invest; 2014 Jul; 124(7):3093-106. PubMed ID: 24911147
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma.
Garzia L; Andolfo I; Cusanelli E; Marino N; Petrosino G; De Martino D; Esposito V; Galeone A; Navas L; Esposito S; Gargiulo S; Fattet S; Donofrio V; Cinalli G; Brunetti A; Vecchio LD; Northcott PA; Delattre O; Taylor MD; Iolascon A; Zollo M
PLoS One; 2009; 4(3):e4998. PubMed ID: 19308264
[TBL] [Abstract][Full Text] [Related]
28. FSTL1 enhances chemoresistance and maintains stemness in breast cancer cells via integrin β3/Wnt signaling under miR-137 regulation.
Cheng S; Huang Y; Lou C; He Y; Zhang Y; Zhang Q
Cancer Biol Ther; 2019; 20(3):328-337. PubMed ID: 30336071
[TBL] [Abstract][Full Text] [Related]
29. miR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1.
Gao M; Miao L; Liu M; Li C; Yu C; Yan H; Yin Y; Wang Y; Qi X; Ren J
Oncotarget; 2016 Sep; 7(37):59714-59726. PubMed ID: 27487127
[TBL] [Abstract][Full Text] [Related]
30. Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog.
Paranjape AN; Balaji SA; Mandal T; Krushik EV; Nagaraj P; Mukherjee G; Rangarajan A
BMC Cancer; 2014 Oct; 14():785. PubMed ID: 25348805
[TBL] [Abstract][Full Text] [Related]
31. MiR-129-3p promotes docetaxel resistance of breast cancer cells via CP110 inhibition.
Zhang Y; Wang Y; Wei Y; Li M; Yu S; Ye M; Zhang H; Chen S; Liu W; Zhang J
Sci Rep; 2015 Oct; 5():15424. PubMed ID: 26487539
[TBL] [Abstract][Full Text] [Related]
32. Increased fucosylation has a pivotal role in multidrug resistance of breast cancer cells through miR-224-3p targeting FUT4.
Feng X; Zhao L; Gao S; Song X; Dong W; Zhao Y; Zhou H; Cheng L; Miao X; Jia L
Gene; 2016 Mar; 578(2):232-41. PubMed ID: 26701615
[TBL] [Abstract][Full Text] [Related]
33. LncRNA SPRY4-IT1 regulates breast cancer cell stemness through competitively binding miR-6882-3p with TCF7L2.
Song X; Zhang X; Wang X; Chen L; Jiang L; Zheng A; Zhang M; Zhao L; Wei M
J Cell Mol Med; 2020 Jan; 24(1):772-784. PubMed ID: 31736268
[TBL] [Abstract][Full Text] [Related]
34. MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells.
Zhong S; Li W; Chen Z; Xu J; Zhao J
Gene; 2013 Nov; 531(1):8-14. PubMed ID: 23994196
[TBL] [Abstract][Full Text] [Related]
35. Doxorubicin and Cisplatin Modulate miR-21, miR-106, miR-126, miR-155 and miR-199 Levels in MCF7, MDA-MB-231 and SK-BR-3 Cells That Makes Them Potential Elements of the DNA-Damaging Drug Treatment Response Monitoring in Breast Cancer Cells-A Preliminary Study.
Mizielska A; Dziechciowska I; Szczepański R; Cisek M; Dąbrowska M; Ślężak J; Kosmalska I; Rymarczyk M; Wilkowska K; Jacczak B; Totoń E; Lisiak N; Kopczyński P; Rubiś B
Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36980974
[TBL] [Abstract][Full Text] [Related]
36. MiR-124 reversed the doxorubicin resistance of breast cancer stem cells through STAT3/HIF-1 signaling pathways.
Liu C; Xing H; Guo C; Yang Z; Wang Y; Wang Y
Cell Cycle; 2019 Sep; 18(18):2215-2227. PubMed ID: 31286834
[TBL] [Abstract][Full Text] [Related]
37. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells.
Li SY; Sun R; Wang HX; Shen S; Liu Y; Du XJ; Zhu YH; Jun W
J Control Release; 2015 May; 205():7-14. PubMed ID: 25445694
[TBL] [Abstract][Full Text] [Related]
38. Enforced expression of hsa-miR-125a-3p in breast cancer cells potentiates docetaxel sensitivity via modulation of BRCA1 signaling.
Xu X; Lv YG; Yan CY; Yi J; Ling R
Biochem Biophys Res Commun; 2016 Oct; 479(4):893-900. PubMed ID: 27693788
[TBL] [Abstract][Full Text] [Related]
39. MiR-375 inhibits the stemness of breast cancer cells by blocking the JAK2/STAT3 signaling.
Zhao Q; Liu Y; Wang T; Yang Y; Ni H; Liu H; Guo Q; Xi T; Zheng L
Eur J Pharmacol; 2020 Oct; 884():173359. PubMed ID: 32738343
[TBL] [Abstract][Full Text] [Related]
40. MiR-221 promotes stemness of breast cancer cells by targeting DNMT3b.
Roscigno G; Quintavalle C; Donnarumma E; Puoti I; Diaz-Lagares A; Iaboni M; Fiore D; Russo V; Todaro M; Romano G; Thomas R; Cortino G; Gaggianesi M; Esteller M; Croce CM; Condorelli G
Oncotarget; 2016 Jan; 7(1):580-92. PubMed ID: 26556862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
